The FDA approved Darzalex Faspro with Velcade, Revlimid and dexamethasone for newly diagnosed multiple myeloma ineligible for autologous stem cell transplant. The U.S. Food and Drug Administration ...

Chronic muscle tension is a common underlying factor in many pain disorders, causing reduced arterial blood flow, tissue hypoxia, and the release of inflammatory mediators. These physiological changes ...

Compared with placebo, significantly greater proportions of patients treated with Tremfya achieved clinical remission and endoscopic improvement. HealthDay News — The US Food and Drug Administration ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved a subcutaneous induction regimen of guselkumab for the treatment of adults with moderately ...

Please provide your email address to receive an email when new articles are posted on . Patients who received subcutaneous amivantamab-vmjw every 4 weeks plus lazertinib had similar outcomes as those ...

Though the PRAETORIAN group was technically unable to prove that 8 years was enough to give a subcutaneous implantable cardioverter-defibrillator (ICD) an edge in safety, complication rates helped ...

The question is not just substitution but how SC therapeutics integration will affect health care delivery at scale. The real question is can we afford to ignore a more efficient, patient-centered ...

Among recipients of subcutaneous implantable cardioverter defibrillators, the omission of defibrillation testing (DT) was not associated with significant differences in mortality, or in the rates of ...

Panelists discuss how subcutaneous (SubQ) drug formulations offer practical value by significantly reducing treatment times, easing staffing pressures, and enhancing efficiency in oncology practices, ...